Corvus ups at-the-market equity facility to $200M from $100M

Corvus Pharmaceuticals, Inc.

Amended Sales Agreement with Jefferies allows up to $200M in common stock sales, increased from $100M.
No shares sold under prior $100M agreement; new ATM offering uses customary terms.
Jefferies to receive up to 3.0% commission; agreements include representations and indemnification.
Prospectus supplement filed; sales may be in negotiated, block, or ATM transactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Corvus Pharmaceuticals, Inc. entered into Amended and Restated Open Market Sale Agreement with Jefferies LLC valued at maximum aggregate offering price of up to $200,000,000 (effective 2026-03-13).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: maximum aggregate offering price of up to $200,000,000
Effective: 2026-03-13

Exact text from the filing

On March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement SM (the “Amended Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having a maximum aggregate offering price of up to $200,000,000.

View on SEC.gov

314 material agreements filed in the last 30 days. Browse all material agreements →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-027390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.